Core Viewpoint - The article discusses the recently approved "Development Plan for Open Innovation of the Biopharmaceutical Industry Chain in China (Jiangsu) Free Trade Pilot Zone," which aims to enhance the biopharmaceutical industry's innovation capabilities and modernize its supply chain by 2030 [2]. Group 1: Key Tasks and Goals - The plan outlines 7 key areas and 18 specific tasks to promote integrated innovation across the entire biopharmaceutical industry chain [2]. - By 2030, the goal is to achieve rapid growth in the biopharmaceutical industry scale, optimize the innovation ecosystem, significantly enhance the modernization level of the industry chain, and improve the level of openness [2]. Group 2: R&D and Innovation - The plan emphasizes the importance of R&D innovation, focusing on advanced treatment methods such as immune cells, stem cells, and gene therapy, as well as innovative medical devices [3]. - Specific measures include strengthening the application of big data and artificial intelligence in drug design and medical device manufacturing, and supporting clinical research in relevant fields [3]. Group 3: Production and Distribution - The plan proposes pilot projects for segmented production of chemical raw materials and biological products, and reforms in the supervision of imported experimental animals [4]. - It aims to enhance the convenience of customs clearance for medical and research materials, leveraging Jiangsu's strong innovation capabilities and complete industry chain [4]. Group 4: Financial Support and Investment - The plan includes significant financial support measures, allowing qualified biopharmaceutical companies to list on various stock exchanges and issue bonds for financing [5]. - It encourages the establishment of investment funds focused on the biopharmaceutical industry and the issuance of real estate investment trusts (REITs) for eligible projects [5]. Group 5: Data Management - The plan highlights the importance of data management in the biopharmaceutical sector, proposing the development of a negative list for data export in this field [6]. - This initiative aims to facilitate efficient data export processes for companies, which is crucial for the overall development of the biopharmaceutical industry [6].